Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium (Q37764163)

22 August 2017

1 reference

title

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium (English)

1 reference

22 August 2017

0 references

1 reference

2

Cora N Sternberg

1 reference

22 August 2017

Nicholas J. Vogelzang

6

object named as

Nicholas J Vogelzang

1 reference

22 August 2017

Guru Sonpavde

1

1 reference

22 August 2017

Jonathan E Rosenberg

3

1 reference

22 August 2017

Noah M Hahn

4

1 reference

22 August 2017

Matthew D Galsky

5

1 reference

22 August 2017

publication date

25 May 2010

1 reference

Lancet Oncology Commission

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

9

1 reference

22 August 2017

page(s)

861-870

1 reference

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

A Phase II study of oxaliplatin in urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Urothelial tumorigenesis: a tale of divergent pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Generation of a concise gene panel for outcome prediction in urinary bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

VEGF receptor expression and signaling in human bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

ASA404: update on drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

Detection of circulating tumor cells in patients with urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970086-3

7 January 2021

10.1016/S1470-2045(10)70086-3

Identifiers

DOI

1 reference

22 August 2017

1 reference